ArticleSkeletal muscle2026
A 3D skeletal muscle system for disease modelling and secretome profiling of Duchenne muscular dystrophy.
Article in Skeletal muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Duchenne muscular dystrophy: from gene to gene-ius therapies.Skeletal muscle · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundDuchenne muscular dystrophy (DMD) is a severe X-linked genetic disease characterized by progressive muscle degeneration, exhaustion of the muscle stem cell pool, and extensive fibrotic remodelling, ultimately leading to loss of function and reduced quality of life. Although conventional cultures and mouse models have provided valuable insights into the pathogenesis of DMD, their mild phenotypes and prolonged disease progression require large sample sizes and lengthy experimental timelines. In turn, the field lacks experimental models that recapitulate the complexity of the dystrophic muscle phenotype in vitro for disease modelling or drug screening.
methodsWe developed a three-dimensional (3D) construct of dystrophic skeletal muscle using a scaffold-free approach, starting from primary cells isolated from the mdx4cv mouse strain, a widely used model of Duchenne muscular dystrophy (DMD). To assess the pathological fidelity of the DMD 3D model, we conducted a thorough morphological and functional characterization. Taking advantage of the controlled and isolated nature of the system, we explored the paracrine role of the derived muscle-extracellular vesicles (EVs), investigating their potential contribution to disease progression.
resultsThe heterogeneous 3D skeletal muscle model of DMD faithfully reproduced the hallmark pathological features observed in patient-derived muscle tissue, including progressive muscle degeneration, fibrotic remodelling, and defective regenerative capacity. Furthermore, it enabled mechanistic investigations of muscle-derived EVs, revealing their ability to propagate both regenerative and catabolic signals.
conclusionsThis 3D model provides a physiologically relevant and reproducible tool for studying the molecular mechanisms underlying DMD and evaluating potential therapeutic interventions, reducing the use of animal models. Its capacity to replicate key aspects of the muscle pathology holds significant potential for identifying novel biomarkers and therapeutic targets, with broad implications for translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.